{"filing":{"accession_number":"0001654954-26-006663","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"a5060m.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006663/a5060m.htm"},"events":[{"id":18052,"run_id":16205,"accession_number":"0001654954-26-006663","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"GSK announces completion of its acquisition of Nuvalent, Inc., a clinical-stage biopharmaceutical company, for approximately $10.6 billion in aggregate equity value (net $9.4 billion). The announcement explicitly states \"GSK completes acquisition of Nuvalent, Inc.\" and describes the transaction as adding three lung cancer assets to GSK's oncology portfolio, including two assets with FDA Breakthrough Therapy designations and expected 2026 launches with \"multi-blockbuster potential.\" This is a material acquisition completion disclosing a substantial change of control and strategic expansion.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":16753,"accession_number":"0001654954-26-006663","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"GSK announces completion of its acquisition of Nuvalent, Inc., a clinical-stage biopharmaceutical company, for approximately $10.6 billion in aggregate equity value (net $9.4 billion). The announcement explicitly states \"GSK completes acquisition of Nuvalent, Inc.\" and describes the transaction as adding three lung cancer assets to GSK's oncology portfolio, including two assets with FDA Breakthrough Therapy designations and expected 2026 launches with \"multi-blockbuster potential.\" This is a material acquisition completion disclosing a substantial change of control and strategic expansion.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:12:40.390479+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-15"}]}